Viyash Scientific liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5.70×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
2.38×	2.38×	1.73×	1.29×	1.48×
1.53×	1.53×	0.97×	0.74×	0.82×
256	256	62.7	67.4	41.6
1,309	1,309	368	184	254

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

VIYASH₹204.52

Viyash Scientific Ltd.

· Pharma & Health

₹ CrorePeersAARTIDRUGS YATHARTH THYROCARE SUPRIYA STAR SPARC SHILPAMED RUBICONMcap ₹8,934 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	5.70
Current Ratio	1.48	1.29	1.73	2.38	2.38
Quick Ratio	0.82	0.74	0.97	1.53	1.53
Cash, Equiv & ST Investments	41.6	67.4	62.7	255.8	255.8
Working Capital	253.7	183.9	367.9	1,308.7	1,308.7

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.